Dr. Edwards manages our IND-enabling toxicology programs. He brings over fifty years of pharmaceutical development, with a strong background in toxicology, DMPK, CMC/manufacturing, regulatory affairs, clinical development, and first-in-human studies.

Dr. Edwards has deep expertise across therapeutic areas, including cardiovascular, CNS, immunology, inflammation, metabolic and oncology. He previously led toxicology teams at Syntex Research, Quintiles Scotland, AtheroGenics Inc. and Salutria Pharma.